ABSTRACT
The prevalence of type 2 diabetes mellitus is increasing at an alarming rate in the United States and around the world (1). It is a very costly disease, both monetarily and in terms of reduced quality of life (2). These costs are the consequence of the multiple debilitating chronic complications of hyperglycemia. The clinician’s therapeutic goal is to avoid and mitigate these complications.
